
Does a 10-rep SaaS sales team need MEDDIC, or is it a framework for enterprise sellers with 9-month cycles?
If you lead sales at an SMB or mid-market SaaS company, the cost of a wrong answer runs both ways. Too little qualification fills the forecast with deals that were never real. Too much buries reps in CRM fields on deals that close in 2 weeks.
This guide helps you decide whether MEDDIC fits your sales motion, how much of it to use and how to roll it out without slowing reps down. It covers the signals that MEDDIC fits, when it's overkill, a qualification-depth table by sales motion, how Avoma's own sales team uses MEDDICC, and the metrics that show whether it's working.
TL;DR
Yes, when deals involve several stakeholders, a business case, a competitive evaluation or a formal approval process. For low-value deals with a single decision-maker, a lighter framework is enough.
MEDDIC stands for Metrics, Economic Buyer, Decision Criteria, Decision Process, Identify Pain, and Champion. It is a sales methodology that provides a structured framework for qualifying and managing sales opportunities. For definitions, discovery questions and a worked example, see the complete MEDDIC sales methodology guide.
In SaaS terms, each criterion answers one practical question:
| Criterion | The SaaS question it answers |
|---|---|
| Metrics | What KPI will this subscription move, and by how much? |
| Economic Buyer | Who approves the spend, and have we spoken to them? |
| Decision Criteria | What must the product do to win the evaluation? |
| Decision Process | What happens between "we like it" and a signed order form? |
| Identify Pain | Why buy now rather than next year? |
| Champion | Who will push this internally when we're not on the call? |
The next question is whether your own deals look like the ones MEDDIC was built for.
MEDDIC was designed for large enterprise sales, and SMB SaaS teams with complex products use it too. The deciding factor is how your buyers buy.
Look for these signals in your pipeline:
If 3 or more of these apply to a meaningful share of your pipeline, structured qualification is likely worth the effort. Treat that threshold as a rule of thumb to test against your own data.
Some deals show none of these signals, and that's where MEDDIC costs more than it returns.
Full MEDDIC is disproportionate when one person can make the buying decision. Common cases:
In these cases, keep the principles and drop the paperwork. Confirm the pain and the decision-maker on the first call, and save full MEDDIC for deals above a complexity threshold you define. Treat MEDDIC as a framework you adapt to your business.
Common Mistake: Requiring all six MEDDIC fields on every deal. Reps learn to fill fields to move deals through stages, and the data stops telling managers anything.
Most SaaS teams sit somewhere between these two ends, which is why depth should vary by motion.
Match qualification depth to the buying process. ACV and company size are weak guides on their own. The table below uses the MEDDIC evidence ladder, which grades each criterion as Unknown, Rep-reported or Buyer-confirmed.
| Sales motion | Typical buying process | Qualification depth | Minimum evidence before forecasting |
|---|---|---|---|
| SMB transactional | One decision-maker, days to close | Light: pain and decision-maker | Pain and signer at Buyer-confirmed |
| SMB consultative | 2 to 3 stakeholders, a few weeks | Core: pain, economic buyer, decision process | Economic buyer named; next steps agreed |
| Mid-market | Buying group, security review, 1 to 3 months | Full MEDDIC | All six at least Rep-reported; Economic Buyer and Decision Process Buyer-confirmed |
| Enterprise SaaS | Committee, procurement, legal, 3+ months | MEDDIC plus Competition and Paper Process | All criteria Buyer-confirmed; mutual action plan |
Cycle lengths are illustrative ranges. Calibrate them against your own CRM data.
Example: One Avoma customer, a B2B SaaS company, uses a different framework at different stages. BANT at SQL decides whether an opportunity is worth working. MEDDPICC through discovery and demo qualifies the buying group and process. Commercial exit gates near close cover signature timelines, SOW and DPA. Managers review each deal against the framework for its current stage.
The six criteria stay the same across segments. What changes is the effort each one takes.
For lighter motions, many teams start with BANT, which raises the question of when to switch.
Use BANT for a fast yes/no on inbound leads when most deals close with 1 or 2 people. Move to MEDDIC when deals stall after your contact says yes, because that usually points to an economic buyer or approval step nobody mapped.
Compare the frameworks in more detail in this BANT sales framework guide.
Avoma's own sales team went one step further and added a seventh criterion.
Our experience working with a lot of sales and customer success teams tells us that MEDDIC is missing one more C: Competition. Knowing who your competitors are, and how your prospects perceive and evaluate them, shapes how you position your product. That is why we at Avoma call it MEDDICC.
Competition shows up inside the other criteria. It shapes the decision criteria buyers set, adds steps to the decision process, and often explains the pain that made them look. For the full treatment of Competition and Paper Process, see the MEDDPICC sales methodology guide.
Avoma's demo calls are scored automatically against a 5-point MEDDICC scorecard alongside Avoma's own sales scorecard.
Questions our reps use in discovery:
For a small team, the main cost of MEDDIC is documentation. Meeting intelligence can take most of that off reps.
With Avoma, you already have the MEDDICC scorecard as a default scorecard template. Just choose the questions you want every sales call to be measured by, and you're all set.
The Avoma AI listens to all the calls and scores them based on the MEDDIC parameters defined by you. Each call gets a score, and managers can start coaching from the lowest-scoring calls.
Avoma can also apply a MEDDICC note template to calls and track methodology coverage at the deal level across meetings and emails.


Once MEDDIC is running, you need a way to tell whether it's helping.
Pick a baseline quarter before rollout and track these metrics:
| Metric | What it tells you |
|---|---|
| % of opportunities with Buyer-confirmed evidence on required criteria | Adoption and evidence quality |
| % of late-stage deals with no confirmed economic buyer | Whether reps reach budget owners before late stages |
| Deals advancing without a confirmed decision process | Stage hygiene |
| Stage-to-stage conversion rates | Whether qualified deals progress |
| Deal slippage (close date pushed) | Whether timelines are realistic |
| Forecast variance (called vs. closed) | Forecast reliability |
| Manager time spent gathering deal context | Admin overhead of reviews |
Changes in these numbers can come from pricing, market conditions or team changes. Compare like-for-like periods or teams before crediting MEDDIC.
Key Takeaway: Adopting MEDDIC is a continuous process. Review these metrics every quarter and adjust the minimum evidence for each stage.
MEDDIC fits SaaS teams whose buyers buy in groups, need a business case or run a formal approval process. Size the framework to each sales motion, roll it out where deals need it, and measure the evidence it produces.
If documentation is what stops your team from using MEDDIC, Avoma records your calls, writes MEDDICC notes, syncs qualification details to your CRM and scores every call against your scorecard. Avoma estimates this saves reps 4+ hours a week on note-taking and CRM updates, time that goes back into selling.
Founder-led sales rarely needs a formal framework, because the founder hears every buyer conversation. Once a startup hires its first account executives and starts forecasting, a light version of MEDDIC gives reps and founders a shared definition of a qualified deal. A practical starting point is to track Identify Pain, Economic Buyer and Decision Process, then add the remaining criteria as deal sizes and buying groups grow.
MEDDIC works for the sales-assisted part of a product-led motion. Self-serve signups don't need it because the user buys without a sales conversation. When a self-serve account turns into an expansion or company-wide deal, a buying group appears, and MEDDIC helps reps find the economic buyer, map the approval process and confirm which usage results matter to the business. Product usage data can supply evidence for Metrics and Identify Pain.
In a typical SaaS setup, account executives own MEDDIC qualification, because the full framework needs several conversations with the buying group. SDRs handle early screening with a lighter framework such as BANT and may capture first signals of pain or the likely decision-maker. A clean handoff passes those notes to the AE, who confirms each criterion with the buyer as the deal progresses.
Both CRMs support MEDDIC through custom fields on the deal or opportunity record. One workable setup is a text field per criterion for the evidence, plus a picklist per criterion for its status, such as Unknown, Rep-reported or Buyer-confirmed. Required fields by pipeline stage in HubSpot, or validation rules in Salesforce, can block a stage change until key criteria are filled. Keeping the field count small limits data entry for reps.
MEDDICC adds Competition to MEDDIC's six criteria. SaaS teams that face a competitive shortlist on most deals gain from tracking it as its own criterion, since a buyer's comparison with other vendors shapes decision criteria and timing. Teams that compete mainly against the status quo can keep MEDDIC and record the do-nothing option under Identify Pain. Avoma's own sales team uses MEDDICC.


